RNASET2 silencing affects miRNAs and target gene expression pattern in a human ovarian cancer cell model

Turconi,Giovanna; Scaldaferri,Debora; Fabbri,Marco; Monti,Laura; Lualdi,Marta; Pedrini,Edoardo; Gribaldo,Laura; Taramelli,Roberto; Acquati,Francesco

doi:10.3892/ijo.2016.3763

RNASET2 silencing affects miRNAs and target gene expression pattern in a human ovarian cancer cell model

Authors:
- Giovanna Turconi
- Debora Scaldaferri
- Marco Fabbri
- Laura Monti
- Marta Lualdi
- Edoardo Pedrini
- Laura Gribaldo
- Roberto Taramelli
- Francesco Acquati
View Affiliations

Affiliations: Department of Theoretical and Applied Sciences, University of Insubria, Varese, Italy, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy, JRC Directorate F - Health, Consumers and Reference Materials, Chemical Safety and Alternative Methods Unit, Ispra, Varese (VA), Italy
Published online on: November 9, 2016 https://doi.org/10.3892/ijo.2016.3763
Pages: 2637-2646

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ribonucleases (RNases) are hydrolytic enzymes endowed with the ability to either process or degrade ribonucleic acids. Among the many biological functions assigned to RNases, a growing attention has been recently devoted to the control of cancer growth, in the attempt to bring novel therapeutic approaches to clinical oncology. Indeed, several enzymes belonging to different ribonuclease families have been reported in the last decade to display a marked oncosuppressive activity in a wide range of experimental models. The human RNASET2 gene, the only member of the highly conserved T2/Rh/S family of endoribonucleolytic enzymes described in our species, has been shown to display oncosuppressive roles in both in vitro and in vivo models representing several human malignancies. In the present study, we extend previous findings obtained in ovarian cancer models to shed further light on the cell-autonomous roles played by this gene in the context of its oncosuppresive role and to show that RNASET2 silencing can significantly affect the transcriptional output in one of the most thoroughly investigated human ovarian cancer cell lines. Moreover, we report for the first time that RNASET2-mediated changes in the cell transcriptome are in part mediated by its apparent ability to affect the cell's microRNA expression pattern.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Sopik V, Iqbal J, Rosen B and Narod SA: Why have ovarian cancer mortality rates declined? Part I Incidence Gynecol Oncol. 138:741–749. 2015. View Article : Google Scholar
3	Dahiya N and Morin PJ: MicroRNAs in ovarian carcinomas. Endocr Relat Cancer. 17:F77–F89. 2010. View Article : Google Scholar :
4	Li SD, Zhang JR, Wang YQ and Wan XP: The role of microRNAs in ovarian cancer initiation and progression. J Cell Mol Med. 14:2240–2249. 2010. View Article : Google Scholar : PubMed/NCBI
5	Katz B, Tropé CG, Reich R and Davidson B: MicroRNAs in Ovarian Cancer. Hum Pathol. 46:1245–1256. 2015. View Article : Google Scholar : PubMed/NCBI
6	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
7	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
8	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
9	Acquati F, Morelli C, Cinquetti R, Bianchi MG, Porrini D, Varesco L, Gismondi V, Rocchetti R, Talevi S, Possati L, et al: Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. Oncogene. 20:980–988. 2001. View Article : Google Scholar : PubMed/NCBI
10	Monti L, Rodolfo M, Lo Russo G, Noonan D, Acquati F and Taramelli R: RNASET2 as a tumor antagonizing gene in a melanoma cancer model. Oncol Res. 17:69–74. 2008.PubMed/NCBI
11	Smirnff P, Roiz L, Algelkovitch B, Schwartz B and Shoseyov O: A recombinant human RNASET2 glycoprotein with antituorigenic and antiangiogenic characteristics. Cancer. 107:2760–2769. 2006. View Article : Google Scholar
12	Acquati F, Bertilaccio S, Grimaldi A, Monti L, Cinquetti R, Bonetti P, Lualdi M, Vidalino L, Fabbri M, Sacco MG, et al: Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proc Natl Acad Sci USA. 108:1104–1109. 2011. View Article : Google Scholar :
13	Acquati F, Lualdi M, Bertilaccio S, Monti L, Turconi G, Fabbri M, Grimaldi A, Anselmo A, Inforzato A, Collotta A, et al: Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis. Proc Natl Acad Sci USA. 110:8140–8145. 2013. View Article : Google Scholar : PubMed/NCBI
14	Lualdi M, Pedrini E, Rea K, Monti L, Scaldaferri D, Gariboldi M, Camporeale A, Ghia P, Monti E, Tomassetti A, et al: Pleiotropic modes of action in tumor cells of RNASET2, an evolutionary highly conserved extracellular RNase. Oncotarget. 6:7851–7865. 2015. View Article : Google Scholar : PubMed/NCBI
15	Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, et al: Orchestrating high-throughput genomic analysis with bioconductor. Nat Methods. 12:115–121. 2015. View Article : Google Scholar : PubMed/NCBI
16	Huang W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
18	Vidalino L, Monti L, Haase A, Moro A, Acquati F, Taramelli R and Macchi P: Intracellular trafficking of RNASET2, a novel component of P-bodies. Biol Cell. 104:13–21. 2012. View Article : Google Scholar
19	Eulalio A, Behm-Ansmant I and Izaurralde E: P bodies: At the crossroads of post-transcriptional pathways. Nat Rev Mol Cell Biol. 8:9–22. 2007. View Article : Google Scholar
20	Wang L, Zhu MJ, Ren AM, Wu HF, Han WM, Tan RY and Tu RQ: A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One. 9:e964722014. View Article : Google Scholar : PubMed/NCBI
21	Corradetti MN, Inoki K and Guan KL: The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem. 280:9769–9772. 2005. View Article : Google Scholar : PubMed/NCBI
22	Luhtala N and Parker R: T2 Family ribonucleases: Ancient enzymes with diverse roles. Trends Biochem Sci. 35:253–259. 2010. View Article : Google Scholar : PubMed/NCBI
23	Acquati F, Possati L, Ferrante L, Campomenosi P, Talevi S, Bardelli S, Margiotta C, Russo A, Bortoletto E, Rocchetti R, et al: Tumor and metastasis suppression by the human RNASET2 gene. Int J Oncol. 26:1159–1168. 2005.PubMed/NCBI
24	Kumar S, Nag A and Mandal CC: A comprehensive review on miR-200c, a promising cancer biomarker with therapeutic potential. Curr Drug Targets. 16:1381–1403. 2015. View Article : Google Scholar : PubMed/NCBI
25	Li XY, Li H, Bu J, Xiong L, Guo HB, Liu LH and Xiao T: Prognostic role of microRNA-200c-141 cluster in various human solid malignant neoplasms. Dis Markers. 2015:9356262015. View Article : Google Scholar : PubMed/NCBI
26	Acquati F, Monti L, Lualdi M, Fabbri M, Sacco MG, Gribaldo L and Taramelli R: Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells. Oncotarget. 2:477–484. 2011. View Article : Google Scholar : PubMed/NCBI
27	Cuaz-Pérolin C, Furman C, Larigauderie G, Legedz L, Lasselin C, Copin C, Jaye M, Searfoss G, Yu KT, Duverger N, et al: REDD2 gene is upregulated by modified LDL or hypoxia and mediates human macrophage cell death. Arterioscler Thromb Vasc Biol. 24:1830–1835. 2004. View Article : Google Scholar : PubMed/NCBI
28	Haud N, Kara F, Diekmann S, Henneke M, Willer JR, Hillwig MS, Gregg RG, Macintosh GC, Gärtner J, Alia A, et al: rnaset2 mutant zebrafish model familial cystic leukoencephalopathy and reveal a role for RNase T2 in degrading ribosomal RNA. Proc Natl Acad Sci USA. 108:1099–1103. 2011. View Article : Google Scholar : PubMed/NCBI
29	Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW and Kim S: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
30	Chen Y, Zhang L and Hao Q: Candidate microRNA biomarkers in human epithelial ovarian cancer: Systematic review profiling studies and experimental validation. Cancer Cell Int. 13:86–94. 2013. View Article : Google Scholar : PubMed/NCBI
31	Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, et al: The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 18:85–95. 2010. View Article : Google Scholar : PubMed/NCBI
32	Cochrane DR, Howe EN, Spoelstra NS and Richer JK: Loss of miR-200c: A marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol. 2010:8217172010. View Article : Google Scholar : PubMed/NCBI
33	Chen D, Zhang Y, Wang J, Chen J, Yang C, Cai K, Wang X, Shi F and Dou J: MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117⁺CD44⁺ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res. 6:50–60. 2013. View Article : Google Scholar
34	Guo R, Wu Q, Liu F and Wang Y: Description of the CD133⁺ subpopulation of the human ovarian cancer cell line OVCAR3. Oncol Rep. 25:141–146. 2011.